Last reviewed · How we verify

VIVUS LLC — Portfolio Competitive Intelligence Brief

VIVUS LLC pipeline: 7 marketed, 0 filed, 1 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

7 marketed 0 filed 1 Phase 3 3 Phase 2 9 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Stendra AVANAFIL marketed Phosphodiesterase 5 Inhibitor [EPC] cGMP-specific 3',5'-cyclic phosphodiesterase Hematology 2012-01-01
Phentermine and Topiramate Phentermine and Topiramate marketed
VI-0521 Mid Dose VI-0521 Mid Dose marketed
Stendra 200 mg Stendra 200 mg marketed
Nitrostat Nitrostat marketed Other
VI-0521 Top Dose VI-0521 Top Dose marketed Sympathomimetic amine; appetite suppressant Norepinephrine release; adrenergic system Obesity; Weight Management
VI-0521 VI-0521 marketed Other
Placebo matched phentermine/topiramate Placebo matched phentermine/topiramate phase 3 Sympathomimetic amine + anticonvulsant combination Norepinephrine release (phentermine); carbonic anhydrase, GABA receptors, glutamate receptors (topiramate) Obesity/Weight Management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Eli Lilly · 1 shared drug class
  2. Humanis Saglık Anonim Sirketi · 1 shared drug class
  3. Promomed, LLC · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for VIVUS LLC:

Cite this brief

Drug Landscape (2026). VIVUS LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/vivus-llc. Accessed 2026-05-14.

Related